Skip to main content
SpringerLink
Log in

Treat primary open-angle glaucoma based on needs of the individual, taking potential adherence problems into account

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Glaucoma is a leading cause of visual morbidity and blindness and the incidence increases with advancing age. Topical therapies that reduce intraocular pressure are commonly used as first-line agents to treat primary open-angle glaucoma, with the choice of treatment based on the need of the individual. Agents that are administered once daily with favourable tolerability profiles may lead to high levels of adherence and good treatment outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Broadway DC, Cate H. Pharmacotherapy and adherence issues in treating elderly patients with glaucoma. Drugs Aging. 2015;32(7):569–81.

    Article  PubMed  CAS  Google Scholar 

  2. Nelson WL, Fraunfelder FT, Sills JM, et al. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985. Am J Ophthalmol. 1986;102(5):606–11.

    Article  PubMed  CAS  Google Scholar 

  3. Grierson I, Lee WR, Abraham S. Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol. 1978;62(5):302–13.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  4. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(Suppl 2):S105–10.

    Article  PubMed  Google Scholar 

  5. Krauss AHP, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol. 2004;49(Suppl 1):S5–11.

    Article  PubMed  Google Scholar 

  6. Freedman SF, Freedman NJ, Shields MB, et al. Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol. 1993;116(5):600–11.

    Article  PubMed  CAS  Google Scholar 

  7. Khawaja AP, Chan MP, Broadway DC, et al. Systemic medication and intraocular pressure in a British population: the EPIC-Norfolk Eye Study. Ophthalmology. 2014;121(8):1501–7.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects: serum chemical analysis. Arch Ophthalmol. 1977;95(8):1378–82.

    Article  PubMed  CAS  Google Scholar 

  9. Toris CB, Tafoya ME, Camras CB, et al. Effects of apraclonidine on aqueous humor dynamics in human eyes. Ophthalmology. 1995;102(3):456–61.

    Article  PubMed  CAS  Google Scholar 

  10. Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2 %) [in French]. J Fr Ophtalmol. 2000;23(8):763–8.

    PubMed  CAS  Google Scholar 

  11. Hopes M, Broadway DC. Preservative-free treatment in glaucoma is a sensible and realistic aim for the future. Eur Ophthalmol Rev. 2010;4:23–8.

    Article  Google Scholar 

  12. Drance SM, Bensted M, Schulzer M. Pilocarpine and intraocular pressure: duration of effectiveness of 4 percent and 8 percent pilocarpine instillation. Arch Ophthalmol. 1974;91(2):104–6.

    Article  PubMed  CAS  Google Scholar 

  13. D’Alena P, Ferguson W. Adverse effects after glycerol orally and mannitol parenterally. Arch Ophthalmol. 1966;75(2):201–3.

    Article  PubMed  Google Scholar 

  14. Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1–9.

    PubMed  PubMed Central  Google Scholar 

  15. Kinoshita H, Taniguchi T, Nishiguchi M, et al. An autopsy case of combined drug intoxication involving verapamil, metoprolol and digoxin. Forensic Sci Int. 2003;133(1–2):107–12.

    Article  PubMed  CAS  Google Scholar 

  16. Lama PJ. Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am J Ophthalmol. 2002;134(5):749–60.

    Article  PubMed  CAS  Google Scholar 

  17. Thomson Healthcare Inc. Interaction effects of apraclonidine, brimonidine, and monoamine oxidase inhibitors. Micromedex 2007 and United States Pharmacopeia 2004.

  18. Tabbara KF, Al-Faisal Z, Al-Rashed W. Interaction between acetazolamine and cyclosporine. Arch Ophthalmol. 1998;116(6):832–3.

    PubMed  CAS  Google Scholar 

  19. Steinert RF, Thomas JV, Boger WP 3rd. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol. 1981;99(1):100–3.

    Article  PubMed  CAS  Google Scholar 

  20. Gray TA, Fenerty C, Harper R, et al. Individualised patient care as an adjunct to standard care for promoting adherence to ocular hypotensive therapy: an exploratory randomised controlled trial. Eye. 2012;26(3):407–17.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    The article was adapted from Drugs Aging 2015;32(7):569–81 [1] by salaried employees of Adis/Springer and was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Treat primary open-angle glaucoma based on needs of the individual, taking potential adherence problems into account. Drugs Ther Perspect 32, 65–68 (2016). https://doi.org/10.1007/s40267-015-0270-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-015-0270-5

    Keywords

    Search

    Navigation